AlzClipp / UniUni – 711274 – 07/29/2025

Each year, FDA’s Center for Drug Evaluation and Research (CDER) approves a wide range of new drug products. FDA provides the scientific and regulatory advice needed to bring safe, effective, high-quality generic alternatives to market, which in turn creates more affordable treatment options for pati

This page contains the Obstetrics, Reproductive and Urologic Drugs Advisory Committee (formerly Bone, Reproductive and Urologic Drugs Advisory Committee) Roster, which lists the current members and the current number of vacancies for the committee.

This guidance is the third in a series of four methodological patient-focused drug development guidances that describe how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers to be used for product development decision-making.

The FDA aspires to assist applicants in developing abbreviated new drug applications (ANDAs). To facilitate the development of an ANDA, agency provides the following resources on ANDA forms and submission requirements.

Lincare, Inc. dba United Medical Home Infusion, Little Rock, AR. State Referral Letter Issued 03/05/2018

Task Description Request Please post to the 2018 Pharmacy Inspections and Related Records Web page
Record Date 03/05/2018
FEI Number 3011564121
Firm Name Lincare, Inc. dba United Medical

Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 09/18/2025
Short Title (70 char) Petscript Inc. Paris, TX. 483 issued 09/18/2025
FEI Number 3010282564
Firm Name Petscript Inc
Record Type 483
State TX
Establishment Type Producer of Sterile and Non-sterile